Evidence map›Paper›PMID 36945359›Full record

ArticlePeerJ2023

An

Melih Özbek, Halil Ibrahim Toy, Yavuz Oktay, Gökhan Karakülah, Aslı Suner, Athanasia Pavlopoulou

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The role and therapeutic value of NUSAP1 in human cancers.Journal of translational medicine · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Melih Özbek *Izmir Biomedicine and Genome Center, Izmir, Turkey.
Halil Ibrahim Toy *Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, United States.
Yavuz OktayIzmir Biomedicine and Genome Center, Izmir, Turkey.ORCID 0000-0002-0158-2693
Gökhan KarakülahIzmir Biomedicine and Genome Center, Izmir, Turkey.ORCID 0000-0001-6706-1375
Aslı SunerFaculty of Medicine, Department of Biostatistics and Medical Informatics, Izmir, Turkey.ORCID 0000-0002-6872-9901
Athanasia PavlopoulouIzmir Biomedicine and Genome Center, Izmir, Turkey.
Izmir University · TRSt. Jude Children's Research Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-grade gliomas (LGG) are central nervous system Grade I tumors, and as they progress they are becoming one of the deadliest brain tumors. There is still great need for timely and accurate diagnosis and prognosis of LGG. Herein, we aimed to identify diagnostic and prognostic biomarkers associated with LGG, by employing diverse computational approaches. For this purpose, differential gene expression analysis on high-throughput transcriptomics data of LGG

Indexed as

Brain NeoplasmsGliomaAmino Acid Transport System y+LGene Expression ProfilingHumansMembrane ProteinsNeoplasm GradingPrognosisAmino Acid Transport System y+LMembrane ProteinsNCKAP1L protein, humanSLC7A7 protein, humanBioinformaticsBiomarkersDiagnosisDifferential gene expression analysisLow-grade gliomasPrognosisSystems biologyTranscriptome analysisWeighted gene co-expression network analysis

Identifiers

PMID36945359
PMCPMC10024901
OpenAlexW4327625364

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read20
table measurements read2
reference markers read15
identifiers read15
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.